EP0804417A1 — Racemisation process for use in the manufacture of levobupivacaine and related piperidinecarboxanilide anaesthetic agents
Assigned to Darwin Discovery Ltd · Expires 1997-11-05 · 29y expired
What this patent protects
An optically-enriched piperidine-2-carboxanilide compound, in which the piperidine is optionally N-alkylated, is racemised by heating the compound in an aqueous medium, provided that the medium includes an organic cosolvent if the compound is N-alkylated. This process is particul…
USPTO Abstract
An optically-enriched piperidine-2-carboxanilide compound, in which the piperidine is optionally N-alkylated, is racemised by heating the compound in an aqueous medium, provided that the medium includes an organic cosolvent if the compound is N-alkylated. This process is particularly valuable, in conjuction with a resolution process, for the manufacture of levobupivacaine.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.